162 related articles for article (PubMed ID: 26592662)
21. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry.
Lavoie P; Boutin M; Auray-Blais C
Anal Chem; 2013 Feb; 85(3):1743-52. PubMed ID: 23248976
[TBL] [Abstract][Full Text] [Related]
22. Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation.
Chien YH; Bodamer OA; Chiang SC; Mascher H; Hung C; Hwu WL
J Inherit Metab Dis; 2013 Sep; 36(5):881-5. PubMed ID: 23109060
[TBL] [Abstract][Full Text] [Related]
23. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease.
Nowak A; Beuschlein F; Sivasubramaniam V; Kasper D; Warnock DG
J Med Genet; 2022 Mar; 59(3):287-293. PubMed ID: 33495303
[TBL] [Abstract][Full Text] [Related]
24. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
[TBL] [Abstract][Full Text] [Related]
25. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy.
Sanchez-Niño MD; Sanz AB; Carrasco S; Saleem MA; Mathieson PW; Valdivielso JM; Ruiz-Ortega M; Egido J; Ortiz A
Nephrol Dial Transplant; 2011 Jun; 26(6):1797-802. PubMed ID: 20504837
[TBL] [Abstract][Full Text] [Related]
26. Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model.
Jabbarzadeh-Tabrizi S; Boutin M; Day TS; Taroua M; Schiffmann R; Auray-Blais C; Shen JS
J Lipid Res; 2020 Nov; 61(11):1410-1423. PubMed ID: 32868283
[TBL] [Abstract][Full Text] [Related]
27. Globotriaosylceramide-induced reduction of K
Rickert V; Kramer D; Schubert AL; Sommer C; Wischmeyer E; Üçeyler N
Exp Neurol; 2020 Feb; 324():113134. PubMed ID: 31778662
[TBL] [Abstract][Full Text] [Related]
28. Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease.
Taguchi A; Ishii S; Mikame M; Maruyama H
Mol Genet Metab Rep; 2023 Mar; 34():100952. PubMed ID: 36624895
[TBL] [Abstract][Full Text] [Related]
29. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients.
Manwaring V; Boutin M; Auray-Blais C
Anal Chem; 2013 Oct; 85(19):9039-48. PubMed ID: 23968398
[TBL] [Abstract][Full Text] [Related]
30. Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease.
Park S; Kim JA; Joo KY; Choi S; Choi EN; Shin JA; Han KH; Jung SC; Suh SH
Cardiovasc Res; 2011 Feb; 89(2):290-9. PubMed ID: 20971723
[TBL] [Abstract][Full Text] [Related]
31. Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease.
Sueoka H; Ichihara J; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(5):e0127048. PubMed ID: 25965380
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Intermediate-Conductance Calcium-Activated K Channel (KCa3.1) and Fibroblast Mitogenesis by α-Linolenic Acid and Alterations of Channel Expression in the Lysosomal Storage Disorders, Fabry Disease, and Niemann Pick C.
Oliván-Viguera A; Lozano-Gerona J; López de Frutos L; Cebolla JJ; Irún P; Abarca-Lachen E; García-Malinis AJ; García-Otín ÁL; Gilaberte Y; Giraldo P; Köhler R
Front Physiol; 2017; 8():39. PubMed ID: 28197106
[TBL] [Abstract][Full Text] [Related]
33. Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease.
Shin YJ; Jeon YJ; Jung N; Park JW; Park HY; Jung SC
Mol Med Rep; 2015 Oct; 12(4):5049-57. PubMed ID: 26135632
[TBL] [Abstract][Full Text] [Related]
34. Targeted inhibition of KCa3.1 channel attenuates airway inflammation and remodeling in allergic asthma.
Yu ZH; Xu JR; Wang YX; Xu GN; Xu ZP; Yang K; Wu DZ; Cui YY; Chen HZ
Am J Respir Cell Mol Biol; 2013 Jun; 48(6):685-93. PubMed ID: 23492185
[TBL] [Abstract][Full Text] [Related]
35. KCa3.1 ion channel: A novel therapeutic target for corneal fibrosis.
Anumanthan G; Gupta S; Fink MK; Hesemann NP; Bowles DK; McDaniel LM; Muhammad M; Mohan RR
PLoS One; 2018; 13(3):e0192145. PubMed ID: 29554088
[TBL] [Abstract][Full Text] [Related]
36. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
37. Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease.
Ishii S; Taguchi A; Okino N; Ito M; Maruyama H
J Biol Chem; 2020 Apr; 295(17):5577-5587. PubMed ID: 32179651
[TBL] [Abstract][Full Text] [Related]
38. Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease.
Nose Y; Fujii H; Goto S; Kono K; Okamoto H; Watanabe K; Nishi S
Mol Genet Metab; 2023 Aug; 139(4):107634. PubMed ID: 37406430
[TBL] [Abstract][Full Text] [Related]
39. Elevated interleukin-8 expression by skin fibroblasts as a potential contributor to pain in women with Fabry disease.
Hofmann L; Grüner J; Klug K; Breyer M; Klein T; Hochheimer V; Wagenhäuser L; Wischmeyer E; Üçeyler N
PLoS One; 2024; 19(4):e0300687. PubMed ID: 38593151
[TBL] [Abstract][Full Text] [Related]
40. A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers.
Dupont FO; Gagnon R; Boutin M; Auray-Blais C
Curr Med Chem; 2013; 20(2):280-8. PubMed ID: 23092136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
